Catheter Related Bloodstream Infection Market is anticipated to reach US$ 80 billion by 2033

The global Catheter Related Bloodstream Infection (CRBSI) Market Size is anticipated to be worth US$ 44.67 billion in 2023 and US$ 80 billion by 2033, with a CAGR of 6%. The expansion of the Catheter-Related Bloodstream Infection market can be ascribed to the rise in the number of people suffering from urinary infections. The market for Catheter-Related Bloodstream Infection increased at a CAGR of 4.5% from 2017 to 2022.

Catheters are predicted to be used more frequently as the frequency of chronic illnesses such as diabetes, cardiovascular disorders, urological disorders, end-stage renal disease, and other chronic conditions rises. This, in turn, is projected to increase the number of Catheter-Related Bloodstream Infection patients.

Although the COVID-19 pandemic had an impact on a variety of end-user industries, it also put strain on the healthcare business. As the number of persons suffering from various ailments surged during the epidemic, so did the demand for catheters. The rate of bloodstream infections increased as more individuals were exposed to catheter use.

Get a PDF Sample with Latest Market Insights@ https://www.futuremarketinsights.com/reports/sample/rep-gb-16130

Furthermore, technological advances play an important role in driving market expansion. Miniaturised catheters, for example, and the use of antimicrobial catheters are predicted to minimise catheter-associated infections. Although key manufacturers are inventing, launching, and presenting safer catheters, the market for catheter-related bloodstream infusions is benefiting from their limited expansion.

Key Takeaways from the Market Study

• By distribution channel, hospital pharmacies are expected to possess 40% market share for Catheter-Related Bloodstream Infections market in 2023.
• By drug class, antimicrobial catheters are expected to possess 35% market share for Catheter-Related Bloodstream Infections in 2023.
• North America is expected to possess 35% market share for Catheter-Related Bloodstream Infection market in 2023.
• Asia Pacific is expected to possess 30% market share for Catheter-Related Bloodstream Infection market in 2023.

“Rise in prevalence of diseases that require catheter are increasing the number of patients suffering from Catheter-Related Bloodstream Infections. This, in turn, is supporting the growth of the market.” states a FMI analyst

To remain ‘ahead’ of your competitors, Ask a Question@ https://www.futuremarketinsights.com/ask-question/rep-gb-16130

Competitive Landscape

Key players in the Catheter-Related Bloodstream Infection are Xellia Pharmaceuticals Ltd, Pfizer, Glenmark Pharmaceuticals Ltd, Fresenius Medical Care, CorMedix, TauroPhar GmbH, Geistlich Pharma, Citus Pharmaceuticals, AstraZeneca Pharma India Ltd, Merck Sharp & Dohme Corp

• In August 2021, Xellia Pharmaceuticals (‘Xellia’), a global leader in the manufacturing of specialty anti-infective treatments, announced that its manufacturing site in Cleveland, Ohio is now commercially operational and has released the first anti-infectives manufactured at the site, to be distributed for use by US hospitals.
• In February 2020, CorMedix, Inc. announced that Neutrolin received grant from the U.S. Food and Drug Administration for the prevention of catheter-related blood stream infections (CRBSIs) in hemodialysis patients.

Key Companies Profiled: 

• Xellia Pharmaceuticals Ltd.
• Pfizer
• Glenmark Pharmaceuticals Ltd.
• Fresenius Medical Care
• CorMedix
• TauroPhar GmbH
• Geistlich Pharma
• Citus Pharmaceuticals
• AstraZeneca Pharma India Ltd.
• Merck Sharp & Dohme Corp

We Offer tailor-made Solutions to fit Your Requirements, Request Customization@ https://www.futuremarketinsights.com/customization-available/rep-gb-16130

Key Segments Profiled in the Catheter-Related Bloodstream Infection Market Industry Survey

Drug Class:

• Non-antibiotic
• Anti-infective
• Antimicrobial

Pathogens:

• Contaminated Catheter Hub
• Contaminated Infusate
• Skin Insertion
• Hematogenous

Source of Infection:

• Aureus
• Aeruginsa
• CONS
• Baumanii
• Coli
• Pnemoniae
• Candida sp

Route of Administration:

• Oral
• Intravenous

Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies